Maria Poca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2507179/publications.pdf

Version: 2024-02-01

623574 552653 1,285 25 14 26 citations h-index g-index papers 26 26 26 1321 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Predictors of the need for necrosectomy in patients with walled-off pancreatic necrosis treated with lumen apposition metal stents. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 1339-1346.	1.3	2
2	Effect of rifaximin on infections, acuteâ€onâ€chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAâ€AH). Liver International, 2022, 42, 1109-1120.	1.9	20
3	Frailty in outpatients with cirrhosis: A prospective observational study. Liver International, 2021, 41, 357-368.	1.9	12
4	Bacteriophages immunomodulate the response of monocytes. Experimental Biology and Medicine, 2021, 246, 1263-1268.	1.1	10
5	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. Journal of Hepatology, 2021, 75, 1026-1033.	1.8	59
6	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology, 2021, 75, 589-599.	1.8	36
7	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368.	2.6	3
8	Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Scientific Reports, 2021, 11, 20415.	1.6	12
9	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4885.	1.0	5
10	Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with \hat{l}^2 -blockers and ligation. Digestive and Liver Disease, 2020, 52, 1017-1025.	0.4	11
11	Short-term hemodynamic effects of \hat{l}^2 -blockers influence survival of patients with decompensated cirrhosis. Journal of Hepatology, 2020, 73, 829-841.	1.8	32
12	Patients with Compensated Cirrhosis Are Also at Risk of Falling. Hepatology, 2019, 69, 455-457.	3.6	1
13	\hat{l}^2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2019, 393, 1597-1608.	6.3	375
14	Ascitic fluid regulates the local innate immune response of patients with cirrhosis. Journal of Leukocyte Biology, 2018, 104, 833-841.	1.5	9
15	Toll-like receptor 4 polymorphisms and bacterial infections in patients with cirrhosis and ascites. World Journal of Hepatology, 2018, 10, 124-133.	0.8	6
16	A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis. Hepatology, 2017, 65, 1693-1707.	3.6	66
17	Development of hyperdynamic circulation and response to βâ€blockers in compensated cirrhosis with portal hypertension. Hepatology, 2016, 63, 197-206.	3.6	143
18	Alteration of the serum microbiome composition in cirrhotic patients with ascites. Scientific Reports, 2016, 6, 25001.	1.6	55

#	Article	lF	CITATIONS
19	Impaired innate immune response of leukocytes from ascitic fluid of patients with spontaneous bacterial peritonitis. Journal of Leukocyte Biology, 2015, 98, 819-825.	1.5	20
20	Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. Journal of Hepatology, 2014, 60, 955-961.	1.8	100
21	Cytokine production in patients with cirrhosis and <i>TLR4</i> polymorphisms. World Journal of Gastroenterology, 2014, 20, 17516.	1.4	17
22	Development of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With \hat{l}^2 -Blockers. American Journal of Gastroenterology, 2012, 107, 418-427.	0.2	115
23	Role of Albumin Treatment in Patients With Spontaneous Bacterial Peritonitis. Clinical Gastroenterology and Hepatology, 2012, 10, 309-315.	2.4	73
24	Cognitive dysfunction in cirrhosis is associated with falls: A prospective study. Hepatology, 2012, 55, 1922-1930.	3.6	93
25	Prognostic markers in patients with cirrhosis and portal hypertension who have not bled. Disease Markers, 2011, 31, 147-54.	0.6	7